Dow Jones -- The U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said it has recommended that Roche Holding AG’s (ROG.VX) cancer drug MabThera be made routinely available on the publicly funded National Health Service to certain patients with chronic lymphocytic leukemia.
